Goldman Sachs Group Inc Ascendis Pharma A/S Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Goldman Sachs Group Inc holds 585,581 shares of ASND stock, worth $92.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

585,581

Previous 585,581 -0.0%

Holding current value

$92.1 Million

Previous $91.3 Million -0.0%

% of portfolio

0.02%

Previous 0.02%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$119.49 - $168.84 $6.59 Million - $9.31 Million	55,164 Added 10.4%	585,581 $91.3 Million
Q4 2024 Feb 11, 2025	BUY	$122.0 - $146.6 $4.89 Million - $5.87 Million	40,066 Added 8.17%	530,417 $73 Million
Q3 2024 Nov 14, 2024	BUY	$113.0 - $153.43 $7.77 Million - $10.6 Million	68,800 Added 16.32%	490,351 $73.2 Million
Q2 2024 Aug 13, 2024	SELL	$121.07 - $153.67 $1.88 Million - $2.39 Million	-15,541 Reduced 3.56%	421,551 $57.5 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $1.76 Million - $2.27 Million	14,238 Added 3.37%	437,092 $66.1 Million
Q4 2023 Feb 13, 2024	BUY	$86.1 - $127.36 $1.11 Million - $1.64 Million	12,881 Added 3.14%	422,854 $53.3 Million
Q3 2023 May 14, 2024	SELL	$86.5 - $103.97 $1.11 Million - $1.34 Million	-12,881 Reduced 3.05%	409,973 $38.4 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $1.11 Million - $1.34 Million	12,882 Added 3.24%	409,973 $38.4 Million
Q2 2023 May 14, 2024	SELL	$69.96 - $97.84 $150 Million - $210 Million	-2,151,054 Reduced 84.42%	397,091 $35.4 Million
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $150 Million - $210 Million	-2,151,054 Reduced 84.42%	397,091 $35.4 Million
Q1 2023 May 14, 2024	BUY	$104.9 - $126.78 $3 Million - $3.63 Million	28,633 Added 1.14%	2,548,145 $273 Million
Q1 2023 May 11, 2023	BUY	$104.9 - $126.78 $3 Million - $3.63 Million	28,633 Added 1.14%	2,548,145 $273 Million
Q4 2022 May 14, 2024	SELL	$99.42 - $131.97 $33.7 Million - $44.7 Million	-338,918 Reduced 11.86%	2,519,512 $308 Million
Q4 2022 Feb 13, 2023	SELL	$99.42 - $131.97 $33.7 Million - $44.7 Million	-338,918 Reduced 11.86%	2,519,512 $308 Million
Q3 2022 May 14, 2024	SELL	$84.03 - $110.23 $38.5 Million - $50.5 Million	-457,785 Reduced 13.8%	2,858,430 $295 Million
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $38.5 Million - $50.5 Million	-457,785 Reduced 13.8%	2,858,430 $295 Million
Q2 2022 May 14, 2024	BUY	$78.08 - $117.61 $226 Million - $340 Million	2,893,361 Added 684.25%	3,316,215 $308 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $122 Million - $184 Million	1,561,757 Added 89.02%	3,316,215 $308 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $174 Million - $231 Million	1,698,302 Added 3024.26%	1,754,458 $206 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $3.2 Million - $4.27 Million	25,188 Added 81.34%	56,156 $7.56 Million
Q3 2021 Nov 10, 2021	BUY	$112.67 - $176.92 $3.49 Million - $5.48 Million	30,968 New	30,968 $4.94 Million

Others Institutions Holding ASND

# of Institutions

270

Shares Held

61.9M

Call Options Held

151K

Put Options Held

226K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.78B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Ascendis Pharma A/S Transaction History